Identification of kitM541l somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response by A. Iurlo et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2014
Identification of kitM541l somatic mutation in chronic eosinophilic 
leukemia, not otherwise specified and its implication in low-
dose imatinib response
Alessandra Iurlo1,2, Umberto Gianelli3, Alessandro Beghini4, Orietta Spinelli5, 
Nicola Orofino1, Francesca Lazzaroni4, Stefano Cambiaghi6, Tamara Intermesoli5, 
Alessandro Rambaldi5 and Agostino Cortelezzi1
1 Hematology and Transplantation Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of Milan, 
Milan, Italy.
2 Oncohematology Unit of the Elderly, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of Milan, 
Milan, Italy.
3 Hematopathology Section, Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan 
Medical School and IRCCS Ca’ Granda – Maggiore Policlinico Hospital Foundation, Milan, Italy
4 Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
5 Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy 
6 Dermatology Unit, IRCCS Ca’ Granda – Maggiore Policlinico Hospital Foundation, Milan, Italy 
Correspondence to: Alessandra Iurlo, email: aiurlo@policlinico.mi.it
Keywords: Chronic Eosinophilic Leukemia, CEL-NOS, KIT541L, KIT mutation, Hypereosinophilic Syndrome. 
Received: April 18, 2014 Accepted: April 30, 2014 Published: May 1, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
Activating mutations of KIT receptor tyrosine kinase have been reported in 
different neoplasms. The M541L KIT substitution (KITM541L) has been described to be 
associated with pediatric mastocytosis, to enhance growth rate of the affected cells 
and to confer higher sensitivity to imatinib therapy. We investigated the presence of 
KITM541L in five males with chronic eosinophilic leukemia, not otherwise specified (CEL, 
NOS), all negative for Platelet-derived growth factor-alpha (PDGFR) or PDGFRbeta 
abnormalities, which responded to imatinib therapy. To assess whether the mutation 
was constitutive or somatic in nature, we evaluated its presence analyzing either the 
neoplastic or normal cell population (epidermal cells or CD3-positive T lymphocytes). 
KITM541L substitution was found in 4 out of 5 patients and in all it was somatic in nature. 
All patients were treated with low dose imatinib (100 mg daily orally), achieving 
complete and persistent clinical and hematological remission (median follow-up 74 
months). One patient relapsed after 50 months. Our study strongly suggests to search 
for the KITM541L in patients with CEL, NOS, negative for PDGFRalpha and PDGFRbeta 
abnormalities, to identify a subgroup of cases who may benefit from low dose imatinib 
therapy.
INTRODUCTION
Hypereosinophilic syndromes are a rare and 
heterogeneous group of disorders characterized 
hypereosinophilia (peripheral blood eosinophils greater 
than 1500/µl), lasting for longer than 6 months, and 
clinical manifestation related to eosinophil accumulation, 
either reactive or neoplastic, within different tissues. 
Clinical features are represented by fatigue, weight loss, 
pruritus, bruising, and signs of organ damage, including 
lung, heart, central and peripheral nervous system, and 
gastrointestinal tract. According to the update WHO 
classification (2008), the group of hypereosinophilic 
syndromes (HES) encompasses myeloid and lymphoid 
neoplasms with eosinophilia and abnormality of 
PDGFRalpha, PDGFRbeta, or FGFR1, chronic 
eosinophilic leukemia, not otherwise specified (CEL, 
NOS) and idiopathic hypereosinophilic syndrome (IHES) 
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[1]. Almost all patients bearing FIP1L1/PDGFRalpha or 
TEL/PDGFRbeta, rearrangements respond to tyrosine 
kinase inhibitors (TKIs), but a striking hematologic 
response can also be observed in about one third of 
patients lacking those genetic lesions [2,3]. Recently, 
we described a case of hypereosinophilic syndrome with 
features of CEL, NOS, carrying the KITM541L variant 
and showing a good response to low-dose imatinib [4]. 
In this context an association between the KIT exon 10 
variants and the clinical response of CEL,NOS to targeted 
treatment by imatinib was suggested.
Activating mutations of the KIT receptor tyrosine 
kinase, whose gene is mapped to human chromosome 
4q12, have been reported in different neoplasms either 
hematological (e.g. acute myeloid leukemia, systemic 
mastocytosis) or non hematological (e.g. gastrointestinal 
stromal tumors, germ cell tumors, melanoma) [5-9].
Together with activating mutations, sequence 
variations (polymorphisms) of the KIT gene have been 
also described (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.
cgi?locusId=3815).
Among them, the M541L variant (KITM541L) has 
been reported to be associated with pediatric mastocytosis, 
to heighten growth response to low levels (< 10 ng/
ml) of Stem-cell Factor (SCF) of the cells carrying this 
substitution, and to confer higher sensitivity to imatinib 
[10]. 
On the basis of these observations we investigated 
the presence of the KITM541L substitution in a cohort of 
CEL,NOS patients who proved negative for PDGFRalpha, 
PDGFRbeta rearrangements, and nevertheless had shoved 
a rapid and robust response to low dose imatinib. 
RESULTS
The main clinical and molecular features of the 5 
patients analyzed in this study are summarized in table 
1 and table 2. They were all male, with a median age at 
diagnosis of 48 years (range: 18-70 years) and diagnosed 
as chronic eosinophilic leukemia, not otherwise specified 
Table 1: Clinical features of five cases of chronic eosinophilic leukemia, not otherwise specified (CEL, NOS).
ID Diagnosis Age Gender
WBC 
(x10^9/L)
Eosinophils
absolute 
count
x10^9/L
and (%)
HB (g/
dL)
PLT 
(x10^9/L)
Organs
Involve
ments
Time to 
CR
Eosinophils
absolute 
count
x10^9/L
and (%) after 
CR
1 CEL-NOS 48 M 9.8 2.1  (21%) 8.7 76 None 1 week 0,02 (0,9%)
2 CEL-NOS 60 M 13.0 1.56 (12%) 12.5 395 None 1 week 0,12 (2%)
3 CEL-NOS 18 M 6.6 2.9 (43%) 14.2 245
Gastro
intestinal
Tract
4 week 0,30 (6%)
4 CEL-NOS 70 M 48.9 28.8 (59%) 14.2 183 none n.a n.a
5 CEL-NOS 45 M 34.9 13.6 (39) 9.9 251 none 4 week 0.17 (3%)
Table 2: Clinical and molecular features of five cases of chronic eosinophilic leukemia, not otherwise specified (CEL, 
NOS).
ID Diagnosis Age Gender Cytogenetic JAK2V
617F
BCR-
ABL
FIP1L1-
PDGF
Ralpha
TEL-
PDGFR
beta c-KIT
Imatinib
response
Follow
-up
1 CEL-NOS 48 M
der(5)t(1;5)
(q25;34),
del5(q?31;q?34)
Neg Neg Neg Neg M541L Yes 120
2 CEL-NOS 60 M del(5)(q32), i(17)(q10); Neg Neg Neg Neg M541L Yes 98
3 CEL-NOS 18 M
46,XY.ish t(4;8)
(q?11;p?11)
(wcp8+;wcp8+)
Neg Neg Neg Neg wt Yes 94
4 CEL-NOS 70 M 46,XY n.a. Neg Neg n.a. M541L Yes 50
5 CEL-NOS 45 M 46,XY Neg Neg Neg Neg M541L Yes 12
Legenda: n.a.: not available; wt.: wild type
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according to the WHO classification [1]. Cytogenetic 
analysis, performed on bone marrow aspirate, revealed 
a normal karyotype in 2 patients (#4 and #5), while 
the presence of chromosomal abnormalities was 
documented in 3 patients. In particular, in patient number 
3 we identified the presence of a translocation between 
chromosomes 4 and 8. Fluorescence in Situ Hybridization 
(FISH) analysis performed on the same sample with 
probes for chromosome 4 and 8 suggested the involvement 
of q11 region on chromosome 4 and p11 region on 
chromosome 8. Additional experiments for breakpoint 
confirmation were not possible at that time.
The polymerase chain reaction (PCR) was found 
negative for the BCR/ABL, FIP1L1/PDGFRalpha 
fusion transcripts and for JAK2 mutations in all cases. 
TEL/PDGFRbeta was analysed in 4 out of 5 patients 
and resulted negative. Serum tryptase was within the 
normal limits or only slightly elevated, but never at the 
mastocytosis range (> 20 ng/ml). Bone marrow aspirates 
and biopsies showed a slightly to moderate hypercellular 
marrow, with normal or decreased erythropoiesis, 
sometimes with associated diserythropoietic findings. 
The granulopoietic series ranged from normal to slightly 
increased, with a constantly higher number of mature 
and immature eosinophils. Megakaryocytes were mature, 
sometimes aggregated in loose clusters, with sparse 
vesicular or hypolobulated nuclei. The percentage of 
CD34-positive hematopoietic precursors was always less 
than 20%. A few round mast cells (less than 5%), tryptase-
positive, CD2 and CD25-negative, were sometimes 
evident in the interstitial space or in perivascular areas. 
Significant collagen fibrosis were absent in all the cases. 
No evidence of myeloproliferative of other hematological 
neoplasms was found in all the cases upon morphological 
and immunohistochemical evaluation.
The molecular analysis showed the presence of the 
KITM541L somatically acquired substitution in 4 out of 5 
cases (#1, 2, 4 and 5). 
Notably, we demonstrated all-heterozigous 
nucleotide exchanges in the 4 patients carrying this genetic 
variant. Moreover, this mutation was present only in the 
neoplastic population while it was absent in epidermal 
cells or T lymphocytes. 
All these patients received a low-dose oral imatinib 
treatment (100 mg daily) and achieved a complete and 
persistent clinical and hematological remission.  With a 
median follow-up of 74 months (range: 12-120 months), 
only one patient (numbered 4 in our series) relapsed after 
50 months. No adverse events were observed during 
imatinib therapy in all the patients. The quality of the 
molecular response was checked during the follow up by 
a direct KIT exon 10 sequencing which was performed on 
genomic DNA obtained from the four CEL, NOS mutated 
patients (Fig.1A).  Within the limited sensitivity of this 
assay (which may detect the mutation in no less than 10% 
of the analyzed cells) the KITM541L was not detectable in 
Figure 1: (A) Representative chromatograms of KIT exon 10 sequence on CEL, NOS patients. The analyses show the presence 
of the genomic variant 4894 A/C (evidenced by arrows) in the neoplastic cell population at diagnosis and its absence in the peripheral 
blood CD3+ T-lymphocytes or skin-derived cells. (B) ARMS-PCR assay for a sensitive detection of the KITM541L substitution in CEL, NOS 
patients at follow up, and BM MNCs from a healthy donor (HD). The assay output shows the persistence of the KITM541L only in the patient 
n. 4.
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all the CEL, NOS patients (data not shown). When using 
a higher sensitive approach (the ARMS assay, which may 
detect this allele variant with a sensitivity close to 3%) 
persistent cells harbouring KITM541L allele variant occurred 
only in one patient (#4), (Fig.1B).
DISCUSSION
In this study we found the presence of a KITM541L 
allele variant in four out of five CEL, NOS patients. 
We were able to demonstrate the somatic nature of this 
nucleotide substitution which was present only in the 
neoplastic population, while it was absent in epidermal 
cells or T lymphocytes. In addition, we found that 
imatinib, which is effective in FIP1L1-PDGFRalpha 
rearrangement positive hypereosinophilic syndromes [11], 
was highly effective also in cases bearing this KITM541L 
variant. Finally these results have been observed using 
a low dose imatinib as in FIP1L1-PDGFRalpha positive 
syndromes.
The intracellular tyrosine kinase activity of the 
transmembrane receptor KIT (CD117), is stimulated 
after binding of the ligand Stem cell Factor (SCF) to 
extracellular domain. KIT is expressed in hematopoietic 
progenitor cells, mast cells, interstitial cells of Cajal, 
germ cells and melanocytes. Activating mutations 
of this gene are considered to play a key role in the 
pathogenesis of various myeloid neoplasms (including 
acute myeloid leukemia and mastocytosis), characterized 
by increasing eosinophil precursors that are part of the 
malignant clone, but have not been found so far in primary 
hypereosinophilic syndromes [12].
The KITM541L has been described as a polymorphic 
variant with allele frequencies at heterozygous  state 
close to 20%. It has been suggested that the constitutive 
expression of KITM541L variant confers a higher sensitivity 
to imatinib in padiatric mastocytosis [10] and in aggressive 
fibromatosis [13]. Furthermore, it was demonstrated the 
presence of the KITM541L variant in cell line of Merkel-cell 
carcinoma (MCC) and an autocrine stimulatory loop was 
suggested between SCF and KIT in a MCC-1 cell line 
which carries the M541L sequence variation [14].
Notably, we were able to demonstrate the somatic 
nature of this substitution and that low-dose imatinib 
was highly effective in cases of CEL,NOS bearing it. 
These findings could explain the optimal and durable 
responsiveness to imatinib treatment frequently reported 
also in patients lacking any known TKI-sensitive genetic 
lesions. Although this sequence variation has not been 
suggested as a disease-causing mutation, the high 
frequency of clinical association and the somatic nature 
of the variants, suggest to reconsider the overall role of 
KIT receptor and its variants in the evolution of chronic 
eosinophilic leukemia.
Our data therefore strongly suggest to search 
at diagnosis for the KITM541L in all the patients with 
hyperheosinophilic syndrome negative for PDGFRalpha, 
PDGFRbeta abnormalities, to identify an additional 
subgroup of patients that may benefit from imatinib 
therapy. Notably, our findings provide evidence that all 
of the four treated patients positive for KITM541L displayed 
a good response to low dose imatinib, supporting and 
extending the relevant observations that juxtamembrane 
KIT mutants display enhanced sensitivity to the kinase-
inhibitory drug imatinib [15,16]. 
We are aware that our observations are limited due 
to the low number of the investigated patients and the good 
response to imatinib therapy obtained also for the single 
patients without the KITM541L mutation. For these reasons 
and considering that CEL, NOS is a rare disorders, further 
studies with  a higher number of patients are necessary to 
estimate the real frequency of this mutation and the impact 
of the imatinib therapy.
METHODS
We retrospectively collected data from five patients, 
fulfilling the criteria for CEL, NOS according to the 
updated WHO classification [1], followed between January 
2003 and December 2012 at two Italian Hematological 
Departments (IRCCS Ca’ Granda – Maggiore Hospital 
Foundation, Milan and Azienda Ospedaliera Papa 
Giovanni XXIII, Bergamo, Italy) which responded to 
low-dose imatinib. These patients were submitted to an 
extensive cytogenetic and molecular analysis including 
BCR/ABL, TEL/PDGFRbeta, FIP1L1/PDGFRalpha 
translocations and JAK2 mutations. Moreover, c-KIT 
analysis on exons 8, 9, 10, 11, 13, 14, and 17 was also 
performed. Bone marrow aspirates and biopsies were 
collected from all of these patients.
Cell separation and molecular analyses
Total nucleated cells (TNC) were collected from 
peripheral blood or bone marrow by Hetasep (StemCell) 
sedimentation. CD3 positive cells were purified from 
whole peripheral blood by immuno-magnetic selection 
using a commercial kit on a semi-automatic instruments 
(Robosep, Stem Cell Technologies Inc. Vancouver, 
Canada). Total RNA was extracted using a column 
based system (Qiagen, Hilden, Germany) and analyzed 
for the presence of FIP1L1/PDGFRalpha [11], TEL/
PDGFRbeta [17] and BCR/ABL [18] fusion transcripts 
as previously described. Genomic DNA was obtained 
by a salting out method (Qiagen, Hilden, Germany) 
following the manufacturer instructions. The presence of 
the JAK2V617F mutation was studied on DNA samples 
by allele specific PCR [19] and mutations in JAK2 exon 
12 was explored by PCR amplification of the whole exon 
12 followed by Sanger sequencing [20].
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KIT mutation analysis
Isolation of genome DNA from polymorphonuclear 
blood cells was performed using DNAzol reagent, 
according to the manufacturer’s instruction (Invitrogen, 
San Paolo, Brazil).
The PCR amplification of c-KIT exons (8, 9, 10, 
11, 17) was performed as previously described [12]. DNA 
sequencing of purified PCR products was carried out 
on an ABI PRISM 3130 XL Genetic Analyzer (Applied 
Biosystems, Darmstadt, Germany). Cycle sequencing 
was conducted using 20 ng of purified PCR fragments. 
Cycling conditions were as follows: 96°C for 1 min; 25 
cycles at 96°C for 10 sec, 50°C for 5 sec; 60°C for 4 min. 
The results were analyzed using the ChromasPro software 
(version 1.41 Technelysium).
In order to assess whether KITM541L substitution 
was constitutive or somatic in nature, we investigated its 
presence in the 4 mutated patients (numbered 1, 2, 4, 5 
in our series) also in the epidermal cells obtained from 
healthy skin by punch biopsies (patients number 5), or in 
CD3-positive T lymphocytes (patients 1, 2, and 4). All the 
patients gave their informed consent.
Amplification Refractory Mutation System (ARMS) 
for KITM541L during the follow-up
The PCR method known as Amplification Refractory 
Mutation System (ARMS) [21] was carried out on 
genomic DNA obtained from CEL, NOS patients at follow 
up. The target DNA (95 bp product) was amplified using 
a couple of forward primers specific for the KIT 4894/C 
(5’-ATGATGTGCATTATTGTGC-3’) genomic variant 
or for the 4894/A (5’-ATGATGTGCATTATTGTGA-3’) 
normal allele respectively, and a common reverse primer 
(5’-TGTCAAGCAGAGAATGGGT-3’). 
The amplification on the thermal cycler was carried 
out consisting of 28 cycles: each cycle consisted of 
denaturation at 94°C for 30 sec, primer annealing at 64°C 
for 15 sec and extension at 72°C for 20 sec. In the final 
cycle the extension was prolonged for another 3 minutes. 
The PCR products was visualized after electrophoresis on 
a 2% agarose gel.
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